Citigroup
TLSI icon

Citigroup’s TriSalus Life Sciences TLSI Stock Holding History

Citigroup’s Portfolio TLSI Stock Details TLSI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$102K Buy
22,515
+20,442
+986% +$81.2K ﹤0.01% 4672
2026
Q1 		$8.29K Buy
2,073
+1,385
+201% +$6.78K ﹤0.01% 5112
2025
Q4 		$4.8K Buy
688
+329
+92% +$1.84K ﹤0.01% 5255
2025
Q3 		$1.67K Sell
359
-5,068
-93% -$23.7K ﹤0.01% 5525
2025
Q2 		$29.6K Buy
5,427
+4,469
+466% +$24K ﹤0.01% 4977
2025
Q1 		$5.29K Buy
+958
New +$5.1K ﹤0.01% 5266

Other funds holding TLSI

FLAM
First Light Asset Management Edina, Minnesota $1.65B AUM 203.21% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Cerity Partners
Cerity Partners New York $82.7B AUM 28.53% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $3.01B AUM 119.46% 1-Year Est. Return
GGHC
Gilder Gagnon Howe & Co New York $9.69B AUM 55.7% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
WPC
White Pine Capital Bloomington, Minnesota $423M AUM 67.01% 1-Year Est. Return
TSW
Thompson Siegel & Walmsley Richmond, Virginia $5.57B AUM 9.46% 1-Year Est. Return

Citigroup's TLSI Position: Q2 2026 in Review

Citigroup increased its TriSalus Life Sciences (TLSI) stake by 986% in Q2 2026, buying an estimated $81.2K and bringing the position to 22,515 shares worth $102K. The position accounts for ﹤0.01% of the portfolio, ranked #4672.

Citigroup first reported a position in TLSI in Q1 2025 and has held it in 6 quarters since. 78 funds tracked by Wall St. Rank hold TLSI as of Q2 2026.

  • Citigroup held 22,515 shares of TriSalus Life Sciences worth $102K as of Q2 2026.
  • Citigroup bought 20,442 TriSalus Life Sciences shares in Q2 2026, an estimated $81.2K.
  • TriSalus Life Sciences made up ﹤0.01% of Citigroup's portfolio in Q2 2026, its #4672 holding.
  • Citigroup first reported a position in TriSalus Life Sciences in Q1 2025 and has held it in 6 quarters since.
  • 78 funds tracked by Wall St. Rank held TriSalus Life Sciences as of Q2 2026.

Based on Citigroup's 13F filing for Q2 2026, filed 3 Aug 2026.